A Phase 3 interventional study of Travoprost/Brinzolamide fixed combination and Azopt in Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Terminated at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-09-19.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 93 studies in Glaucoma by Alcon — none open to participants now, none under way, none of them phase 3. Glaucoma · Alcon.
Among the 93 studies in Glaucoma by Alcon, this one is the 74th largest by enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2008, is one of 26 in phase 3, and was the 42nd registered.
1,419 studies on the registry are indexed under Glaucoma; 221 are open to participants now.
Browse Glaucoma studies →None of the 93 studies in Glaucoma by Alcon is open now. The open studies under Glaucoma, anywhere →
Of the 155 Glaucoma studies recruiting now, 113 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
93 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 19 · Phase 3 26 · Phase 4 37
First in 1999; this study’s year is marked. 7 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 112 across the 77 interventional studies, 95 across the 6 observational. Of the 92 that completed or were terminated, 35 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 93 studies in Glaucoma by Alcon, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare the IOP lowering efficacy of Travoprost/Brinzolamide dosed daily in the morning or evening, vs TRAVATAN dosed once daily in the evening, and vs. AZOPT dosed BID in patients with open-angle glaucoma or ocular hypertension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Related to disease condition being investigated (OAG or OHT) in either eye
Related to ocular patient history or current ocular condition in either eye
Related to systemic or ocular medication in either eye
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost/Brinzolamide AM, Vehicle PM
Drug: Travoprost/Brinzolamide fixed combination
Travoprost/Brinzolamide PM, Vehicle AM
Drug: Travoprost/Brinzolamide fixed combination
AZOPT AM and PM
Drug: Azopt
TRAVATAN PM, Vehicle AM
Drug: Travatan
Mean IOP
Time frame: 9, 11, and 16:00 time points at Week 12
Mean diurnal IOP at Week 12
Time frame: results pooled across 9,11, and 16:00 time points
The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.